Venus Remedies Stock Hits All-Time High of Rs.699 Amid Strong Performance

On 20 Nov 2025, Venus Remedies demonstrated robust market activity, opening with a gap up of 3.13% and touching an intraday high of Rs.699, representing an 8.2% rise within the trading session. The stock outperformed its sector by 6.61% and the broader Sensex by 4.60 percentage points, with a day change of 4.80% compared to Sensex's 0.20%. This performance is part of a recent upward trend, with the stock gaining for two consecutive days and delivering a 24.15% return over this period.

Volatility was notably high, with an intraday volatility of 63.43% calculated from the weighted average price, indicating active trading and investor engagement. Venus Remedies is currently trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a strong technical position in the market.

Examining Venus Remedies' performance over various time frames highlights its market resilience. The stock's returns over the last one year stand at 130.08%, significantly surpassing the Sensex's 10.03% return for the same period. Year-to-date returns are also strong at 114.82%, compared to the Sensex's 9.24%. Over longer horizons, Venus Remedies has delivered 246.03% returns over three years and an impressive 435.60% over five years, both markedly higher than the Sensex's respective 38.43% and 94.52%. Even on a decade scale, the stock's 469.87% return outpaces the Sensex's 229.97%, reflecting sustained growth and value creation.

These returns are complemented by the company's financial fundamentals. Venus Remedies maintains a low average debt-to-equity ratio of zero, indicating a debt-free capital structure. The company reported a net profit after tax (PAT) of Rs.20.13 crores in the latest quarter, reflecting a growth of 473.5% compared to previous periods. This surge in profitability aligns with four consecutive quarters of positive results, underscoring consistent operational performance.

Further financial metrics reinforce the company's efficiency and valuation. The return on capital employed (ROCE) for the half-year period reached a peak of 13.99%, while the inventory turnover ratio stood at a high 6.58 times, signalling effective asset utilisation. The return on equity (ROE) is recorded at 10.5%, paired with a price-to-book value of 1.5, suggesting an attractive valuation relative to peers and historical averages.

Venus Remedies' market-beating performance is evident not only in the long term but also in the near term. The stock's 1-month return of 49.43% and 3-month return of 39.60% substantially exceed the Sensex's 1.18% and 4.28% respectively. Similarly, the 1-week return of 19.84% contrasts with the Sensex's 1.04%, highlighting the stock's momentum across multiple time frames.

Despite the company's size and strong financials, domestic mutual funds currently hold no stake in Venus Remedies. This absence of mutual fund ownership may reflect a cautious stance or differing perspectives on valuation and business prospects within institutional circles.

In summary, Venus Remedies' ascent to an all-time high of Rs.699 is supported by a combination of strong market returns, solid financial metrics, and technical indicators. The stock's performance across various periods and its fundamental strengths position it as a noteworthy entity within the Pharmaceuticals & Biotechnology sector.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →